-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma

Selective recruitment of G protein-coupled receptor kinases (GRKs) controls signaling of the insulin-like growth factor 1 receptor

(2012) H. Zheng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular Mechanism of β-Arrestin-Biased Agonism at Seven-Transmembrane Receptors

(2011) Eric Reiter et al.   Annual Review of Pharmacology and Toxicology

Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells

(2011) Zohar Attias-Geva et al.   EUROPEAN JOURNAL OF CANCER

Polyubiquitination of Insulin-like Growth Factor I Receptor (IGF-IR) Activation Loop Promotes Antibody-induced Receptor Internalization and Down-regulation

(2011) Yifan Mao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma

(2011) Heribert Juergens et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantifying Ligand Bias at Seven-Transmembrane Receptors

(2011) S. Rajagopal et al.   MOLECULAR PHARMACOLOGY

Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma

(2011) S. Yin et al.   NEURO-ONCOLOGY

A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs

(2011) E L McKinsey et al.   ONCOGENE

Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling

(2011) C Garofalo et al.   ONCOGENE

Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor

(2011) A Girnita et al.   ONCOGENE

Distinct Phosphorylation Sites on the  2-Adrenergic Receptor Establish a Barcode That Encodes Differential Functions of  -Arrestin

(2011) K. N. Nobles et al.   Science Signaling

Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling

(2011) Arun K. Shukla et al.   TRENDS IN BIOCHEMICAL SCIENCES

β-arrestin-mediated receptor trafficking and signal transduction

(2011) Sudha K. Shenoy et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Pathologic Complete Responses After Chemotherapy Plus Figitumumab in Stage IV Non–Small-Cell Lung Cancer

(2010) Jesús Corral et al.   JOURNAL OF CLINICAL ONCOLOGY

Teaching old receptors new tricks: biasing seven-transmembrane receptors

(2010) Sudarshan Rajagopal et al.   NATURE REVIEWS DRUG DISCOVERY

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

(2009) David Olmos et al.   LANCET ONCOLOGY

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

(2009) A Gualberto et al.   ONCOGENE

Identification of c-Cbl as a New Ligase for Insulin-like Growth Factor-I Receptor with Distinct Roles from Mdm2 in Receptor Ubiquitination and Endocytosis

(2008) B. Sehat et al.   CANCER RESEARCH

Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor

(2008) Matthieu Broussas et al.   INTERNATIONAL JOURNAL OF CANCER

New Picropodophyllin Analogs via Palladium-Catalyzed Allylic Alkylation−Hiyama Cross-Coupling Sequences

(2008) Maxime Vitale et al.   JOURNAL OF ORGANIC CHEMISTRY